GANX

Over the past six months, Gain Therapeutics' stock price has been influenced by several events. In December 2025, the company's price target was increased, and analysts reiterated "buy" recommendations. In January 2026, positive initial Phase 1b results for GT-02287 in Parkinson's disease were presented, showing a significant reduction in cerebrospinal fluid glucosylsphingosine levels and early clinical improvement signals. In March 2026, Gain Therapeutics reported its 2025 year-end financial results, including a net loss of $20.2 million and a cash balance of $20.8 million, while the stock gained approximately 5% since January 31, 2026, due to positive earnings surprises and encouraging Phase 1b clinical data. Despite these positive developments, the stock experienced a decline of 7.65% between May 8, 2025, and May 7, 2026. As of April 12, 2026, analysts gave the stock a consensus recommendation of "Moderate Buy" with an average twelve-month target price of $8.50.